Back to Search
Start Over
A redox-responsive prodrug for tumor-targeted glutamine restriction.
- Source :
-
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2024 Apr; Vol. 368, pp. 251-264. Date of Electronic Publication: 2024 Feb 29. - Publication Year :
- 2024
-
Abstract
- Modulating the metabolism of cancer cells, immune cells, or both is a promising strategy to potentiate cancer immunotherapy in the nutrient-competitive tumor microenvironment. Glutamine has emerged as an ideal target as cancer cells highly rely on glutamine for replenishing the tricarboxylic acid cycle in the process of aerobic glycolysis. However, non-specific glutamine restriction may induce adverse effects in unconcerned tissues and therefore glutamine inhibitors have achieved limited success in the clinic so far. Here we report the synthesis and evaluation of a redox-responsive prodrug of 6-Diazo-5-oxo-L-norleucine (redox-DON) for tumor-targeted glutamine inhibition. When applied to treat mice bearing subcutaneous CT26 mouse colon carcinoma, redox-DON exhibited equivalent antitumor efficacy but a greatly improved safety profile, particularly, in spleen and gastrointestinal tract, as compared to the state-of-the-art DON prodrug, JHU083. Furthermore, redox-DON synergized with checkpoint blockade antibodies leading to durable cures in tumor-bearing mice. Our results suggest that redox-DON is a safe and effective therapeutic for tumor-targeted glutamine inhibition showing promise for enhanced metabolic modulatory immunotherapy. The approach of reversible chemical modification may be generalized to other metabolic modulatory drugs that suffer from overt toxicity.<br />Competing Interests: Declaration of competing interest C.P., N.B., L.T. and X.H. are inventors on a filed patent related to the redox-DON. L.T. is a co-founder, share-holder, and advisor for Leman Biotech. The interests of L.T. were reviewed and managed by EPFL. The remaining authors declare no competing interests.<br /> (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1873-4995
- Volume :
- 368
- Database :
- MEDLINE
- Journal :
- Journal of controlled release : official journal of the Controlled Release Society
- Publication Type :
- Academic Journal
- Accession number :
- 38403173
- Full Text :
- https://doi.org/10.1016/j.jconrel.2024.02.031